Novavax to Participate in the BofA Securities 2023 Health Care Conference

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

News Market Reaction – NVAX

The recorded move for NVAX in the trading session of this news was +1.85%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/04/2023 - 04:02 PM EDT

GAITHERSBURG, Md., May 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the BofA Securities 2023 Health Care Conference.

Conference Details:
Fireside Chat
Date:		Thursday, May 11, 2023
Time:		10:00 – 10:30 a.m. Pacific Daylight Time (PDT)
Location:		Encore Hotel in Las Vegas, Nevada
Moderator:		Alec Stranahan, Ph.D., Equity Research Analyst – Biotechnology
Novavax participants:		John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development

Conference
Event:		Investor Meetings
Date:		Wednesday, May 10, 2023 - Thursday, May 11, 2023

Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined.

Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com

Media
Ali Chartan or Giovanna Chandler | 240-709-5563
media@novavax.com